A carregar...
Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer
This study was conducted with the aim to investigate the feasibility of intermittent treatment with docetaxel chemotherapy for castration-resistant prostate cancer (CRPC). A total of 51 men with CRPC received docetaxel at 75 mg/m(2) every 3 weeks combined with oral dexamethasone 1.0-2.0 mg/day betwe...
Na minha lista:
| Publicado no: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4360872/ https://ncbi.nlm.nih.gov/pubmed/25798258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2014.469 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|